Skip to Main Content

Promising new therapies are springing up to treat ovarian cancer, long one of the most deadly and hard to treat malignancies.

The latest: An experimental drug from Tesaro, a small biotech company based in Waltham, Mass. The company on Wednesday released exciting clinical trial data for an experimental drug that’s meant to stop cancer cells from repairing themselves after they’ve been hit by chemotherapy.


Patients with recurring ovarian cancer who took the drug got as much as an additional 15 months with no growth in their tumors, as compared to a control group, the company said. The data hasn’t yet been peer reviewed or analyzed by federal regulators but the company press release on the results sent stock prices soaring.

The catch? Even with new drugs, ovarian cancer mortality is likely to remain high.

One reason: Geography.


Patients who aren’t treated at well-trafficked oncology centers tend to receive suboptimal treatment for this confounding cancer, researchers are showing. They don’t always get therapies that could give them many more months of life. And as drug regimens become more nuanced and complicated, requiring genetic sequencing of tumors, this treatment gap is at risk of growing.

“It’ll get worse,” said Dr. Leslie Randall, an associate professor of gynecologic oncology at the University of California, Irvine. “As we come out with more novel treatments that are more complex to deliver, that disparity will only get worse.”

A 2015 study that examined ovarian cancer treatment and survival between 1996 and 2006 found that patients treated at comprehensive care centers certified by the National Cancer Institute had survival rates nearly double other women. Another study from UC Irvine found that black women received substandard care and had lower survival rates than their peers.

“Part of the disparity is that if patients don’t live in an area with a specialized cancer center, they’re not getting the cutting-edge standard of care,” said Dr. Thomas Morrissey, a gynecologic oncologist at Cleveland Clinic.

With a five-year, $1.9 million grant from the National Institutes of Health, researchers at UC Irvine are now delving deeper into ovarian cancer treatment disparities by race and socioeconomic status. They hope to develop better nationwide guidelines of care.

A silent killer

Ovarian cancer patients have long had limited treatment options. In fact, the treatment paradigm hasn’t much changed in two decades: First comes surgery to remove tumors, followed by chemotherapy.

Because early symptoms are fairly benign — bloating and back pain — about 75 percent of women diagnosed with ovarian cancer don’t learn they have it until it has progressed to Stage 3. About 22,000 new cases are diagnosed each year, and about 15,000 women die of the disease each year in the United States.

“It’s hard to diagnose people with ovarian cancer, because it’s so rare. There’s no screening, no Pap smear, no mammogram that will easily tell you that you have ovarian cancer,” said Dr. Rebecca Liu, a gynecologic oncologist at University of Michigan Health System.

Many oncologists were bitterly disappointed this spring when a major trial of a promising new way to deliver chemotherapy failed to show benefits.

But the burgeoning field of pharmacogenomics — the study of how an individual’s genes affect her response to a specific drug — offers new hope, said Dr. Lee Shulman, the chief of the obstetrics and gynecology clinical genetics program at Northwestern University’s Feinberg School of Medicine.

An intriguing new class of drugs

Tesaro’s drug, called niraparib, belongs to an intriguing new class of medication called PARP inhibitors that work by stopping cancerous cells from repairing damage done by chemotherapy. A genomic analysis of the patient can show whether the drugs are likely to help her.

Another PARP inhibitor, called olaparib, marketed as Lynparza by AstraZeneca, is already being used for certain types of ovarian cancer.

Beyond PARP inhibitors, researchers are looking at an array of treatment mechanisms.

Monoclonal antibodies such as Genentech’s Avastin are being used, with promise, in treating ovarian cancer. They latch onto cancerous cells and interfere with their growth. Scientists and doctors also see promise in therapies designed to boost the immune system and send it into attack mode against tumors.

“The field of immuno-oncology is huge for melanoma, lung cancer, kidney cancer, bladder cancer — and for ovarian cancer, it’s just getting started,” Randall said.

Though Tesaro’s drug has not yet been approved by the Food and Drug Administration, the company’s shares shot up 108 percent Wednesday, closing at $77.64, on word of the trial results. The international study enrolled more than 500 women with recurring ovarian cancer and found the drug “significantly prolonged” the amount of time before tumors started growing again, necessitating another round of chemotherapy, though it did not look at whether patients lived longer on the drug.

Women both with and without genetic mutations that raise the risk of ovarian cancer benefited from the drug, the company said. The most common side effects were a platelet deficiency that can slow blood clotting and anemia.

“We were bullish before the data, I would say, and I’m characterizing myself as even more bullish now that now that we’ve seen it,” said Chris Raymond, an analyst and managing director at Raymond James Financial. “This is the best case scenario by almost any measure.”

Comments are closed.